AstraZeneca PLC
Truqap
PTEN-deficient metastatic hormone-sensitive prostate cancer
Resolved
67days ago
Advisory committee · May 1, 2026
What's at stake
An FDA advisory committee reviews Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer around May 1, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 14h ago
“The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy ”